Although any factor causing an increased risk of developing a de novo germline pathogenic variant in RB1 should cause an increase in the number of bilateral retinoblastoma patients, one cannot be certain that the increase is not due to a change in the small proportion of the patients with somatic pathogenic variants in RB1 within the group. This evidence concerns the gene RB1 and retinoblastoma.